1. bookVolume 60 (2022): Issue 1 (March 2022)
Journal Details
License
Format
Journal
eISSN
2501-062X
First Published
30 Mar 2015
Publication timeframe
4 times per year
Languages
English
access type Open Access

Anti-dense fine speckled (DFS) antibody: its staining pattern in indirect immunofluorescence and its clinical relevance

Published Online: 17 Mar 2022
Page range: 66 - 76
Received: 26 Jun 2021
Journal Details
License
Format
Journal
eISSN
2501-062X
First Published
30 Mar 2015
Publication timeframe
4 times per year
Languages
English
Abstract

Background: Dense fine speckled (DFS) pattern is defined by very intense, heterogeneous speckled staining of nucleoplasms of interphase HEp-2 cells and chromosomal areas of metaphase cells. The association of Anti-DFS70 and rheumatologic signs, symptoms, and diagnosis were evaluated.

Methods: One-hundred-eight anti-DFS70 positives who got consecutively admitted to the Rheumatology clinic between January and June 2020 were analyzed. The clinical and laboratory findings of positives for anti-DFS70 antibody were compared with those with DFS pattern ANA IFA staining rates. Also, anti-DFS70 positivity rates and their correlation with the DFS staining pattern were analyzed retrospectively in 1016 CTD patients.

Results: The most common complaint was joint pain seen in 77 (71.3%) and the most common laboratory abnormality was RF-positivity observed in 10/108 (9.3%) who had anti-DFS70 positivity. The most common ANA staining pattern was DFS (72/108; 66.7%); one-third had other than DFS. No statistical significance was found for the association of any of the rheumatological complaints and laboratory findings with the DFS staining pattern. ANA analysis was performed in a total of 964/1016 (94.88%) CTD patients and 44 (4.56%) of these positive for anti-DFS70. The correlation coefficient showed good correlations between the DFS pattern staining and anti-DFS70 antibody positivity (r=+0.773, p<0.001).

Conclusions: Anti-DFS70-positives have a low rate of CTD. A low anti-DFS70 positivity rate was observed in patients with CTD. As such, it can be considered that anti-DFS70 does not predict CTD or even excludes it.

Keywords

1. PİSETSKY DS, LİPSKY PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol. 2020 Oct;16(10):565–79.10.1038/s41584-020-0480-7Search in Google Scholar

2. NOSAL RS, SUPERVİLLE SS, VARACALLO M. Biochemistry, Antinuclear Antibodies (ANA). In Treasure Island (FL); 2021.Search in Google Scholar

3. CHAN EKL, DAMOİSEAUX J, CARBALLO OG, CONRAD K, DE MELO CRUVİNEL W, FRANCESCANTONİO PLC, et al. Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014-2015. Front Immunol. 2015;6:412.10.3389/fimmu.2015.00412Search in Google Scholar

4. GANAPATHY V, CASİANO CA. Autoimmunity to the nuclear autoantigen DFS70 (LEDGF): what exactly are the autoantibodies trying to tell us? Arthritis and rheumatism. United States; 2004;50:684–8.Search in Google Scholar

5. OCHS RL, STEİN TWJ, PEEBLES CL, GİTTES RF, TAN EM. Autoantibodies in interstitial cystitis. J Urol. 1994;151(3):587–92.10.1016/S0022-5347(17)35023-1Search in Google Scholar

6. BİZZARO N, TONUTTİ E, VİSENTİNİ D, ALESSİO MG, PLATZGUMMER S, MOROZZİ G, et al. Antibodies to the lens and cornea in anti-DFS70-positive subjects. Ann N Y Acad Sci. 2007;1107:174–83.10.1196/annals.1381.019Search in Google Scholar

7. DANİELS T, ZHANG J, GUTİERREZ I, ELLİOT ML, YAMADA B, HEEB MJ, et al. Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate. 2005;62(1):14–26.10.1002/pros.20112Search in Google Scholar

8. OCHS RL, MURO Y, Sİ Y, GE H, CHAN EK, TAN EM. Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol. 2000;105(6 Pt 1):1211–20.10.1067/mai.2000.107039Search in Google Scholar

9. AYAKİ M, OHOGURO N, AZUMA N, MAJİMA Y, YATA K, IBARAKİ N, et al. Detection of cytotoxic anti-LEDGF autoantibodies in atopic dermatitis. Autoimmunity. 2002;35(5):319–27.10.1080/0891693021000003198Search in Google Scholar

10. OKAMOTO M, OGAWA Y, WATANABE A, SUGİURA K, SHİMOMURA Y, AOKİ N, et al. Autoantibodies to DFS70/LEDGF are increased in alopecia areata patients. J Autoimmun. 2004;23(3):257–66.10.1016/j.jaut.2004.07.004Search in Google Scholar

11. YAMADA K, SENJU S, SHİNOHARA T, NAKATSURA T, MURATA Y, ISHİHARA M, et al. Humoral immune response directed against LEDGF in patients with VKH. Immunol Lett. 2001;78(3):161–8.10.1016/S0165-2478(01)00243-7Search in Google Scholar

12. YUMUK Z, DEMİR M. Clinical value of anti-DFS70 antibodies in a cohort of patients undergoing routine antinuclear antibodies testing. J Immunol Methods. 2020;480:112754.10.1016/j.jim.2020.112754Search in Google Scholar

13. LA JEON Y, KANG SY, LEE W-I, KİM MH. Clinical Aspects of the Dense Fine Speckled Pattern in Indirect Immunofluorescence-Antinuclear Antibody Screening and Its Association with DFS70 Autoantibodies. Ann Clin Lab Sci. 2019;49(4):496–502.Search in Google Scholar

14. PASHNİNA IA, KRİVOLAPOVA IM, FEDOTKİNA T V, RYABKOVA VA, CHERESHNEVA M V, CHURİLOV LP, et al. Antinuclear Autoantibodies in Health: Autoimmunity Is Not a Synonym of Autoimmune Disease. Antibodies (Basel, Switzerland). 2021;10(1).10.3390/antib10010009Search in Google Scholar

15. SEELİG CA, BAUER O, SEELİG H-P. Autoantibodies Against DFS70/LEDGF Exclusion Markers for Systemic Autoimmune Rheumatic Diseases (SARD). Clin Lab. 2016;62(4):499–517.10.7754/Clin.Lab.2015.150905Search in Google Scholar

16. MULHEARN B, TANSLEY SL, MCHUGH NJ. Autoantibodies in connective tissue disease. Best Pract Res Clin Rheumatol. 2020;34(1):101462.10.1016/j.berh.2019.101462Search in Google Scholar

17. ALMEİDA GONZÁLEZ D, ROCES VARELA A, MARCELİNO RODRÍGUEZ I, GONZÁLEZ VERA A, DELGADO SÁNCHEZ M, AZNAR ESQUİVEL A, et al. Anti-dsDNA antibodies in systemic lupus erythematosus: A combination of two quantitative methods and the ANA pattern is the most efficient strategy of detection. J Immunol Methods. 2015;427:30–5.10.1016/j.jim.2015.09.003Search in Google Scholar

18. MAHLER M, PARKER T, PEEBLES CL, ANDRADE LE, SWART A, CARBONE Y, et al. Anti-DFS70/LEDGF Antibodies Are More Prevalent in Healthy Individuals Compared to Patients with Systemic Autoimmune Rheumatic Diseases. J Rheumatol 2012;39(11):210410.3899/jrheum.120598Search in Google Scholar

19. PEPMUELLER PH. Undifferentiated Connective Tissue Disease, Mixed Connective Tissue Disease, and Overlap Syndromes in Rheumatology. Mo Med. 2016;113(2):136–40.Search in Google Scholar

20. INFANTİNO M, SHOVMAN O, PÉREZ D, MANFREDİ M, GROSSİ V, BENUCCİ M, et al. Anti-DFS70 autoantibodies in undifferentiated connective tissue diseases subjects: what’s on the horizon? Rheumatology (Oxford). 2018;57(7):1293–8.10.1093/rheumatology/key012Search in Google Scholar

21. ROMERO-ÁLVAREZ V, ACERO-MOLİNA DA, BELTRÁN-OSTOS A, BELLO-GUALTEROS JM, ROMERO-SÁNCHEZ C. Frequency of ANA/DFS70 in Relatives of Patients with Rheumatoid Arthritis Compared to Patients with Rheumatoid Arthritis and a Healthy Population, and its Association with Health Status. Reumatol Clin. 2021;17(2):67–73.10.1016/j.reuma.2019.02.003Search in Google Scholar

22. HAYASHİ N, UTO K, IMANİSHİ A, SUGİYAMA D, MORİNOBU A, SAEGUSA J. Prevalence of anti-dense fine speckled 70 antibodies in healthy individuals and patients with antinuclear antibody-associated autoimmune rheumatic diseases in Japan. Medicine (Baltimore). 2021;100(9):e24556.10.1097/MD.0000000000024556Search in Google Scholar

23. MURO Y, SUGİURA K, MORİTA Y, TOMİTA Y. High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody-positive patients with autoimmune rheumatic disease. Lupus. 2008;17(3):171–6.10.1177/0961203307086311Search in Google Scholar

24. WATANABE A, KODERA M, SUGİURA K, USUDA T, TAN EM, TAKASAKİ Y, et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum. 2004;50(3):892–900.10.1002/art.20096Search in Google Scholar

25. CHOİ MY, CLARKE AE, ST PİERRE Y, HANLY JG, UROWİTZ MB, ROMERO-DİAZ J, et al. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus. 2017;26(10):1051–9.10.1177/0961203317692437Search in Google Scholar

26. KANG SY, LEE WI, KİM MH, LA JEON Y. Clinical use of anti-DFS70 autoantibodies. Rheumatol Int. 2019;39(8):1423–9.10.1007/s00296-019-04299-4Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo